{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fostamatinib",
    "query": {
      "intervention": "Fostamatinib"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fostamatinib&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T03:23:27.033Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02076412",
      "title": "A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immune Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Fostamatinib Disodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2015-01",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2019-01-25",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 1,
      "location_summary": "Nyack, New York",
      "locations": [
        {
          "city": "Nyack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076412"
    },
    {
      "nct_id": "NCT01309854",
      "title": "Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Healthy Volunteers",
        "Pharmacokinetics",
        "Pioglitazone",
        "Drug-drug Interaction",
        "Amount of Pioglitazone in Blood"
      ],
      "interventions": [
        {
          "name": "fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2011-03",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2011-07-07",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01309854"
    },
    {
      "nct_id": "NCT01264770",
      "title": "Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Fostamatinib and placebo injections",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab and placebo of fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo of fostamatinib, fostamatinib, and placebo injections",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 644,
      "start_date": "2011-01",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-06",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264770"
    },
    {
      "nct_id": "NCT04543279",
      "title": "Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis",
        "Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-05-03",
      "completion_date": "2022-07-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-15",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04543279"
    },
    {
      "nct_id": "NCT01197755",
      "title": "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2010-09",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2014-04-07",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 67,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01197755"
    },
    {
      "nct_id": "NCT04138927",
      "title": "A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Warm Antibody Autoimmune Hemolytic Anemia"
      ],
      "interventions": [
        {
          "name": "Fostamatinib disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 90,
      "start_date": "2019-10-30",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04138927"
    },
    {
      "nct_id": "NCT00805467",
      "title": "Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Fostamatinib Disodium (R935788)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 624,
      "start_date": "2008-08",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2014-06-25",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 35,
      "location_summary": "La Jolla, California • Palm Desert, California • Palo Alto, California + 32 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00805467"
    },
    {
      "nct_id": "NCT00798096",
      "title": "Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fostamatinib Disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2009-03",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2016-09-19",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798096"
    },
    {
      "nct_id": "NCT02077192",
      "title": "Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immune Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Fostamatinib Disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2014-10",
      "completion_date": "2020-06-02",
      "has_results": true,
      "last_update_posted_date": "2023-12-11",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Peoria, Illinois • Lafayette, Indiana + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02077192"
    },
    {
      "nct_id": "NCT01245790",
      "title": "A Study of Fostamatinib in Subjects With Impaired Kidney Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "fostamatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2010-11",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2011-06-16",
      "last_synced_at": "2026-09-03T03:23:27.033Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01245790"
    }
  ]
}